Literature DB >> 3084017

Increase in bronchopulmonary infection due to branhamella catarrhalis.

D T McLeod, F Ahmad, S Capewell, M J Croughan, M A Calder, A Seaton.   

Abstract

In a six month prospective study during the winter Branhamella catarrhalis was isolated from the sputum of 63 patients with symptoms of bronchopulmonary infection: 49 isolates were in pure culture and 14 were with another pathogen, Haemophilus influenzae being the commonest (found with 10 of the 14 B catarrhalis isolates). Of 36 patients infected in the community, 26 required admission to hospital. The remaining 27 patients were infected while in hospital. Forty four of the 63 isolates produced beta lactamase; 26 of these had been acquired in the community. As a result 29 patients were treated inappropriately with ampicillin and did not respond to this treatment. beta Lactamase produced by B catarrhalis may also protect other pathogens normally susceptible to beta lactam antibiotics. Most patients had chronic lung diseases or lung cancer, but three otherwise healthy patients who did not smoke developed bronchitis. B catarrhalis contributed to the death of five patients. A survey of the antibiotic prescribing habits of the referring general practitioners together with the sensitivity results of B catarrhalis suggest that changes in antibiotic prescribing habits in the community may be responsible for the increase in B catarrhalis infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084017      PMCID: PMC1340037          DOI: 10.1136/bmj.292.6528.1103

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  10 in total

1.  IgA protease production as a characteristic distinguishing pathogenic from harmless neisseriaceae.

Authors:  M H Mulks; A G Plaut
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

2.  The aetiology of acute otitis media in children. Occurrence of bacteria, L forms of bacteria and mycoplasma in the middle ear exudate. Relationship between bacterial findings in the middle ear exudate, nasopharynx and throat.

Authors:  C Kamme; K Lundgren; P A Märdh
Journal:  Scand J Infect Dis       Date:  1971

3.  Branhamella catarrhalis prevalence in a hospital population.

Authors:  F Ahmad; D T McLeod; J T Power; M A Calder
Journal:  J Hosp Infect       Date:  1985-03       Impact factor: 3.926

4.  Fatal Neisseria (Branhamella) catarrhalis pneumonia in an immunodeficient host.

Authors:  D J McNeely; C S Kitchens; R M Kluge
Journal:  Am Rev Respir Dis       Date:  1976-08

5.  In vitro sensitivity to penicillin V and beta-lactamase production of Branhamella catarrhalis.

Authors:  B E Malmvall; J E Brorsson; J Johnsson
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

6.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

7.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

8.  Branhamella catarrhalis pneumonia and immunoglobulin abnormalities: a new association.

Authors:  L A Diamond; B Lorber
Journal:  Am Rev Respir Dis       Date:  1984-05

9.  Bronchopulmonary infection due to Branhamella catarrhalis.

Authors:  D T McLeod; F Ahmad; J T Power; M A Calder; A Seaton
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12

10.  Comparison of trimethoprim alone with trimethoprim sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance.

Authors:  R W Lacey; V L Lord; H K Gunasekera; P J Leiberman; D E Luxton
Journal:  Lancet       Date:  1980-06-14       Impact factor: 79.321

  10 in total
  20 in total

1.  Labile type-specific antigen of Moraxella catarrhalis.

Authors:  S J Norkus; J W Vennes
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

Review 2.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

Review 3.  The penicillins today.

Authors:  R Finch
Journal:  BMJ       Date:  1990-05-19

4.  Antigenic heterogeneity and molecular analysis of CopB of Moraxella (Branhamella) catarrhalis.

Authors:  S Sethi; J M Surface; T F Murphy
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Respiratory tract infections due to Branhamella catarrhalis: epidemiological data from Western Australia.

Authors:  C DiGiovanni; T V Riley; G F Hoyne; R Yeo; P Cooksey
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

6.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  Outbreak of Moraxella catarrhalis in a respiratory unit.

Authors:  S J Richards; A P Greening; M C Enright; M G Morgan; H McKenzie
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

Review 8.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

9.  A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.

Authors:  M E Helminen; I Maciver; J L Latimer; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 10.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.